

# ACS care with unprecedented diagnostic confidence

Speed meets confidence with Elecsys® Troponin T hs Gen 6, advancing rapid and safe ACS triage

**ED overcrowding** is recognized as a global health delivery problem or healthcare challenge.[1]

**Up to 10%** of **male and female** adult ED visits are chest pain-related.[2]




**Approximately 1 in 20** chest-pain patients have a life-threatening AMI.[3]



**Rapid rule-out** to avoid unnecessary treatment and overcrowding.[4]

**Rapid rule-in** to ensure early identification of AMI and timely intervention.[5]



## Accelerate your rule-out decisions without compromising on safety

### From analytical performance to clinical confidence

High sensitivity at even lower troponin levels,[6] helping to boost confidence in decision-making.

+

Market-leading hemoglobin interference resistance, reducing resampling and enhancing lab efficiency.[6-8]

**Elecsys® Troponin T hs Gen 6** is globally validated, giving you stronger confidence in your ACS decision.[9-12]

**>11,000** patients

**>10** countries

**4** different cohorts at launch

### Clear and reliable classification

**76%** **of suspected ACS patients can be triaged (rule-out or rule-in) within 1 hour**[10] using assay-specific ESC algorithms, potentially accelerating the AMI diagnosis process and reducing ED workload.[10,11,13]

**ESC 0/1h and 0/2h algorithms cutoffs:**[6]

| | |
|---|---|
| **Rule-out** ✓ | |
| @0h <8 ng/L (if CPO >3h) | |
| @0h <18 ng/L AND Δ1h <2 ng/L | |
| @0h <18 ng/L AND Δ2h <4 ng/L | |
| **Observe** ? | |
| Further assessment | |
| **Rule-in** ! | |
| @0h ≥112 ng/L | |
| @1h Δ ≥10 ng/L | |
| @2h Δ ≥15 ng/L | |

**Clinical performance of the ESC 0/1h algorithm:**[10]

**56%** of suspected NSTEMI patients with very high NPV of 99.9%

**24%** of patients requiring further assessment

**20%** of patients with a high PPV of 73.0%

Similar performance observed with the ESC 0/2h algorithm.[10]

## Enhance cardiovascular risk assessment to improve long-term patient management

### Strong prognostic value of Elecsys® Troponin T hs Gen 6 beyond diagnostic efficiency[10,12,13]

**Patient outcomes**[6]

Excellent short- and long-term prognostic performance, improving triage efficiency and safety at follow-up of:

**30** days | **180** days | **5** years

**Confidence in classification**[6,12]

Clear risk stratification allowing for safe discharge of the rule-out group, and for prioritizing care for rule-in/observe groups.




**Patients ruled out by applying the ESC 0/1h algorithm show:**



**MACE* and all-cause death <0.5% at 30 and 180 days**[10,12,13]

**5-year mortality rate similar to reported rates for the general population** in age-matched studies (2.7% vs 3-6%, respectively)[14]

**MACE* and all-cause death distribution for the ESC 0/1h algorithm**[10,12,13]

| | | Rule-out | Rule-in |
|---|---|---|---|
| 30 days | All-cause death: | 0.12% | 3.09% |
| | MACE: | 0.04% | 3.36% |
| 180 days | All-cause death: | 0.46% | 9.03% |
| | MACE: | 0.26% | 7.71% |
| 1 year | All-cause death: | 0.9% | 12% |
| 5 years | All-cause death: | 2.7% | 25.5% |

MACE data unavailable at 1 and 5 years.
Data derived from multiple independent studies (APACE[10], BACC[12], PERFORM-TSIX[13]). Follow-up duration and endpoints vary across studies.

**Elecsys® Troponin T hs Gen 6 (above 99th percentile URL) can detect myocardial injury associated with an increased risk of MACE* or all-cause death**[6]




**Above 99th percentile** universal URL (27 ng/L), patients are **more likely to experience MACE** or **all-cause death**

| | <3.5 | 3.5-12 | 12-27 | 27-45 | 45-70 | >70 |
|---|---|---|---|---|---|---|
| All-cause death | 619 | 1656 | 1029 | 502 | 328 | 947 |
| MACE | 592 | 1579 | 980 | 469 | 314 | 891 |

## Unlock more efficient pathways with the potential of a one-and-done pathway



The emerging single-sample rule-out strategies use a **single blood sample** to exclude AMI based on low concentrations of hs-cTn and ECG findings.[15]

This approach has the potential to rapidly identify low-risk patients**, allowing for **safe and early discharge from the emergency department.**[11,15]

**99.9%** negative predictive value

**99.4%** sensitivity

**0** MACE* at 30 days

**Elecsys® Troponin T hs Gen 6 is a significant improvement on previous Troponin T generations:**

**41%** of patients in the ED can be ruled out with **1 sample** and a **single baseline cutoff of <13 ng/L.**[11] These results have been further supported by the results in the APACE[10] and PERFORM-TSIX[13] studies.

**By supporting diverse accelerated triage pathways, Elecsys® Troponin T hs Gen 6 can improve ED patient throughput and reduce the burden on healthcare services.**

**These promising, evidence-generating approaches have the potential to improve patient throughput in the ED and reduce the burden on healthcare services.**

*MACE: AMI or cardiac death;
**Patients who present at least 3 hours after the onset of ischemic symptoms.

1. Sartini M, et al. Healthcare. 2022;10(9):1625; 2. Dawson LP, et al. J Am Coll Cardiol. 2022;79:2333–2348; 3. Slankamenac KS, et al. J Clin Cardiol. 2019;1(1):1-15; 4. Januzzi JL, et al. J Am Coll Cardiol. 2018;71:617–619; 5. Byrne RA, et al. Eur Heart J. 2023;44(38):3720-3826; 6. F. Hoffmann-La Roche Ltd. Elecsys® Troponin T hs Gen 6 Method Sheet. (v.3.0).2026; 7. F. Hoffmann-La Roche Ltd. Hemoglobin interference comparison. Data on file; 8. Marques-Garcia F, et al. Ann Lab Med. 2022;42(2):169-177; 9. Daniels LB, et al. Clin Res Cardiol. 2026;DOI:10.1007/s00392-025-02842-x; 10. Koechlin L, et al. 2026. JACC DOI:10.1016/j.jacc.2025.12.052; 11. Thurston F, Early rule-out of myocardial infarction with the novel Troponin T hs Gen 6 assay. Presented at: EUSEM Congress; 2025 Sept 28 – Oct 1; Vienna, Austria; 12. Völschow B, et al. Diagnostic Validation of a novel High-Sensitivity Cardiac Troponin T Assay. NCT02355457. Manuscript in preparation. Data on file; 13. Peacock WF, et al. Primary results of PERFORM-TSIX, a prospective, international, observational, longitudinal cohort study evaluating clinical performance of the next generation cardiac troponin T high-sensitivity Gen 6 assay in acute myocardial infarction. Presented at: EUSEM Congress; 2025 Sept 28 – Oct 1; Vienna, Austria; 14. Eurostat. Life table by age and sex [Internet; cited 2025 Mar 18]. Available from: https://ec.europa.eu/eurostat/databrowser/view/DEMO_MLIFETABLE/default/table?lang=en; 15. Jaffe AS, et al. J Am Coll Cardiol. 2023;82:60–69.

MC-BE-02624